Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas

Keyphrases

• P27 Expression 100%
• Cyclin-dependent Kinase Inhibitor 2A (CDKN2A) 100%
• Malignant Astrocytoma 100%
• Tumor 50%
• Immunohistochemistry 50%
• Overexpression 50%
• Prognostic Value 50%
• Cyclin-dependent Kinase Inhibitor p27 50%
• Therapeutic Implications 50%
• Brain Tumor 50%
• Clinical Characteristics 50%
• Western Analysis 50%
• Malignant Potential 50%
• Human Brain 50%
• Progression-free Survival 50%
• Clinicopathologic Correlation 50%
• Malignant Glioma 50%
• Cyclin-dependent Kinase Inhibitor p21 50%
• Cyclin-dependent Kinase Inhibitor p16 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Astrocytoma 100%
• Cyclin Dependent Kinase Inhibitor 100%
• Cyclin Dependent Kinase Inhibitor 1B 50%
• Glioblastoma 50%
• Progression Free Survival 50%
• Cyclin Dependent Kinase Inhibitor 2A 50%
• Cyclin Dependent Kinase Inhibitor 1A 50%
• Intracranial Tumor 50%

Neuroscience

• Astrocytoma 100%
• Cyclin-Dependent Kinase 100%
• Immunohistochemistry 33%
• Intracranial Tumor 33%
• Human Brain 33%
• Glioma 33%